Emercell and Cell-Easy Sign a Strategic Agreement for the Scale-up and Manufacturing of NK-001
Emercell SAS (Emercell) and Cell-Easy SAS (Cell-Easy) announced today the signing of a strategic agreement for the scale-up and manufacturing of Emercell’s lead product.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220922005449/en/
Emercell has developed a platform technology to produce off-the-shelf natural killer (NK) cells. NK cells are highly potent immune effectors, used alone as monotherapy, or in combination with therapeutic antibodies, or are genetically engineered to produce Chimeric Antigen Receptor (CAR)-NK cells for the treatment of hematological malignancies and solid tumors. NK-001 is an optimized cell therapy product composed of highly activated and alloreactive allogeneic NK cells. Its patented manufacturing process allows a complete industrialization by using the same batch of NK cells for multiple patients.
Cell-Easy is an analytics-driven Contract Development and Manufacturing Organization (CDMO) specialized in the production of Gene-modified Cell and Cell Therapy products. Cell-Easy’s facilities are located in Toulouse including state-of-the-art controlled environment suites optimized for developing manufacturing and analytical processes, proceed to environmental and material Quality Control, and execute cGMP manufacturing, fill & finish, long-term storage of Advanced Therapy Medicinal Products (ATMPs) compliant with all the requirements of regulatory standards and cGMP guidelines.
Emercell has selected Cell-Easy as a long-term CDMO partner for the scale-up and manufacturing operations of its allogeneic NK cell-based product, with the objective to enter clinical phase in 2023. Emercell has signed a strategic agreement with Cell-Easy specialized in the development and production of ATMP.
“We are very pleased to collaborate with Cell-Easy on the final stages of development and GMP manufacturing of our flagship product, NK-001“, said Patrick Henno, President of Emercell.” We are looking forward to a successful and long-lasting collaboration as a key element of our development strategy. Moreover, Cell-Easy and Emercell are located in the Occitanic Region and the partnership fits perfectly with the Region’s objectives regarding the development and production of new products in the field of biotherapies, and particularly in the field of immunotherapy.
In a very competitive European landscape, we are delighted that Emercell has chosen us as their privileged CDMO Partner for their first immune-oncology approach using NK-cells”, said Guillaume Costecalde, President of Cell-Easy. “Cell-Easy CDMAO’s original approach and the team’s reactivity combined with our state-of-the-art facility allow us once again to convince ambitious ATMP developers such as Emercell to secure their development.”
About Emercell
Emercell is an oncology company developing a platform technology to produce off-the-shelf allogenic natural killer (NK) cells. The company's R&D activities are located at the IRMB (Institute of Regenerative Medicine and Biotherapies) at the Saint-Éloi University Hospital Center, Montpellier, France. Emercell's lead drug candidate, NK-001, is intended, among others, for the treatment of lymphoma patients who are refractory to conventional therapies. It is a patented process for pre-activating and amplifying allogeneic NK cells. Emercell collaborates with numerous industrial and academic partners. The company has received the support of the Occitanie Region (ADI) and Bpifrance and has obtained a FUI (financing). Emercell is a member of Eurobiomed.
About Cell-Easy
Cell-Easy developed a unique vision of CDMO dedicated to the production of Cell and Gene modified Cell Therapy products. This integrated concept is called CDMAO. Beyond CDMO, CDMAO is not only focused on Development & Manufacturing. CDMAO is positioned as a real partner for helping Biotech & Pharma to bridge the gap between preclinical and clinical development with in-depth expertise on regulatory process scale-up and analytics.
Cell-Easy offers customized process development, process scale-up, cGMP manufacturing and unique analytical services for immune cells (engineered CAR-T, NK, …cells, and non-engineered cells) and adult stem cells (MSCs, iPSCs and Exosomes) both in Immuno-Oncology and Regenerative Medicine fields.
Cell-Easy is a trusted partner and brings today the infrastructure and know-how while ensuring your projects are delivered on time and budget. Supported by highly motivated and experienced people in the Cell Therapy field, Cell-Easy is committed to driving service excellence and actively contribute to a “Bench to Bedside” culture, putting the healthcare of patients at the center of everything.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220922005449/en/
Contact information
Media and Investor Contacts:
Emercell, Dr. Patrick Henno, President, patrick.henno@emercell.com, (+33)-6-14-77-39-21
Cell-Easy, Dr. Guillaume Lay, Business Development, Guillaume.lay@cell-easy.com, (+33)-6 15 18 13 13
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Reports First Quarter 2024 Results6.5.2024 23:27:00 CEST | Press release
IFF (NYSE: IFF) reported financial results for the first quarter ended March 31, 2024. Management Commentary "We have started the year well, with good results across the majority of our business," said IFF CEO Erik Fyrwald. "In the first quarter, we delivered volume growth and productivity gains, which resulted in solid top-and-bottom-line results on a comparable basis. We are off to a good start, yet recognize that it is still early in the year and uncertainty remains. Based on our performance to date and our outlook for the balance of the year, we believe results will likely trend towards the higher-end of our previously announced guidance ranges. We also took important steps in our portfolio optimization strategy by reaching an agreement to sell our Pharma Solutions business and completing the previously announced divestiture of our Cosmetic Ingredients business. These actions, along with the rightsizing of our dividend earlier this year, represent significant steps toward our commi
IFF Chief Financial and Business Transformation Officer Glenn Richter to retire year end 20246.5.2024 22:16:00 CEST | Press release
IFF (NYSE: IFF) today announced that Glenn Richter, IFF’s Chief Financial and Business Transformation Officer, plans to retire Dec. 31, 2024 after a three-year tenure with the company. A succession process has been initiated to evaluate internal and external candidates to succeed Richter as CFO. “During his time at IFF, Glenn has driven multiple actions to improve our balance sheet and position the company for financial success,” said Erik Fyrwald, IFF CEO. “We have benefited from his experience and commitment to transformation. Notably, the work he has led on portfolio optimization, strategy development and our shared services agenda have positioned IFF to drive long-term profitable market share growth. The Board and I are grateful for all Glenn has helped IFF accomplish, and we appreciate his ongoing leadership of the finance function and support in identifying his successor and ensuring a smooth transition.” Richter has been with IFF since 2021, leading global finance. Before joinin
The Empire State Building Partners with Outward Bound on First-Ever, Full Rappel Down the Building for Charity6.5.2024 20:34:00 CEST | Press release
The Empire State Building (ESB) hosted 20 brave supporters of Outward Bound – along with participant Jared Leto – in a historic rappel down the building’s south façade, in partnership with Outward Bound to raise transformational funds for the charity across the world. Participants total donations exceeded $3 million to Outward Bound, which will make a profound difference in the educational journeys of young people everywhere. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240506846659/en/ The Empire State Building Partners with Outward Bound on First-Ever, Full Rappel Down the Building for Charity (Photo: Business Wire) “The Empire State Building is the perfect host to amplify Outward Bound’s charitable mission through this historic rappel, and it reaffirms the Empire State Building’s long-held status as a symbol of hope, strength, and resilience,” said Tony Malkin, chairman and CEO of Empire State Realty Trust. “My wife and
Armis Wins 6 Global InfoSec Awards at RSAC 2024, Named “Hot” Cybersecurity Company6.5.2024 18:10:00 CEST | Press release
Armis, the asset intelligence cybersecurity company, today announced that it has won six Global InfoSec Awards from Cyber Defense Magazine at this year’s RSA Conference. Armis received the following accolades: Armis named “Hot Cybersecurity Company” Nadir Izrael, Armis’ Co-Founder and CTO, awarded “Cutting Edge Chief Technology Officer” Armis Centrix™ won multiple awards: “Cutting Edge” platform accolade in the Cyber Exposure Management category “Best Product” for Attack Surface Management “Next Gen” product for Vulnerability Prioritization and Remediation The Armis AI-powered Asset Intelligence Engine received a “Publisher’s Choice” award in the category recognizing AI Platforms for Cybersecurity Strategy Analytics “These accolades reinforce Armis’ dedication to innovation and our commitment to helping our customers solve their biggest cybersecurity problems through one comprehensive platform,” said Yevgeny Dibrov, CEO and Co-Founder of Armis. “Armis will continue to push the boundari
Edgio Named Winner of the Coveted Global InfoSec Awards During RSA Conference 20246.5.2024 18:00:00 CEST | Press release
Edgio is proud to announce it has received the Web Application Security award from Cyber Defense Magazine (CDM), the industry’s leading electronic information security magazine. According to Verizon’s Data Breach Investigation Report (DBIR), over 60% of data breaches were attributed to web applications, underscoring the urgent need for organizations to continuously manage threat exposure across their web applications and throughout the entire DevSecOps lifecycle. Committed to addressing the complex and evolving needs of organizations, Edgio continues to innovate and expand its services with its recent launch of Attack Surface Management (ASM) - a solution designed to discover all web assets, provide full inventory of technologies, detect security exposures and manage exposure response across an organization from a centralized management interface. ASM, coupled with Edgio’s holistic web security solutions and managed security services provide the industry’s first edge-enabled continuous